NZ517673A - Chemically-stabilized chlorite solutions for treating cancer and other diseases - Google Patents

Chemically-stabilized chlorite solutions for treating cancer and other diseases

Info

Publication number
NZ517673A
NZ517673A NZ517673A NZ51767300A NZ517673A NZ 517673 A NZ517673 A NZ 517673A NZ 517673 A NZ517673 A NZ 517673A NZ 51767300 A NZ51767300 A NZ 51767300A NZ 517673 A NZ517673 A NZ 517673A
Authority
NZ
New Zealand
Prior art keywords
cancer
carcinoma
cells
macrophages
stabilized chlorite
Prior art date
Application number
NZ517673A
Other languages
English (en)
Inventor
Frederich Kuhne
Vitam Kodelja
Original Assignee
Oxo Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxo Chemie Ag filed Critical Oxo Chemie Ag
Publication of NZ517673A publication Critical patent/NZ517673A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
NZ517673A 1999-08-18 2000-08-18 Chemically-stabilized chlorite solutions for treating cancer and other diseases NZ517673A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14942999P 1999-08-18 1999-08-18
PCT/US2000/022610 WO2001012205A2 (en) 1999-08-18 2000-08-18 Chemically-stabilized chlorite solutions for treating cancer

Publications (1)

Publication Number Publication Date
NZ517673A true NZ517673A (en) 2004-03-26

Family

ID=22530238

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ517673A NZ517673A (en) 1999-08-18 2000-08-18 Chemically-stabilized chlorite solutions for treating cancer and other diseases

Country Status (14)

Country Link
EP (1) EP1408994A2 (zh)
KR (1) KR20020038728A (zh)
CN (1) CN1378456A (zh)
AU (1) AU6913200A (zh)
CA (1) CA2382293A1 (zh)
IL (1) IL148189A0 (zh)
MX (1) MXPA02001724A (zh)
NO (1) NO20020751L (zh)
NZ (1) NZ517673A (zh)
PL (1) PL353769A1 (zh)
RU (1) RU2002106824A (zh)
TR (1) TR200201182T2 (zh)
WO (1) WO2001012205A2 (zh)
ZA (1) ZA200201726B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687238B1 (de) 2003-11-21 2009-12-09 CytoTools AG Reaktive chlorverbindungen, deren derivate, anionen und salze sowie verfahren zu deren herstellung und verwendung
ES2384267T3 (es) * 2005-07-21 2012-07-03 Nuvo Research Ag Soluciones de clorito estabilizadas en combinación con fluoropirimidinas para el tratamiento del cáncer
WO2013093891A1 (en) 2011-12-22 2013-06-27 Nuvo Research Gmbh Liposomal chlorite or chlorate compositions
CN112386606A (zh) * 2019-08-19 2021-02-23 卢序 一种有第二信使作用增加积极氧化压力的氧化剂的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3515749A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Verwendung einer stabilisierten chloritmatrixloesung bei infektioesen zustaenden
DE3515748A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Verwendung einer isotonen chloritmatrix-loesung bei der behandlung von tumoren
DK1021196T3 (da) * 1997-10-06 2004-06-07 Oxo Chemie Ag Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion
WO2000048940A1 (de) * 1999-02-19 2000-08-24 Stahl Kurt Wilhelm Peroxochlorsäure, derivate und anionen, salze davon, und verfahren zu deren herstellung und verwendung

Also Published As

Publication number Publication date
TR200201182T2 (tr) 2002-08-21
WO2001012205A3 (en) 2001-09-13
RU2002106824A (ru) 2003-11-27
EP1408994A2 (en) 2004-04-21
ZA200201726B (en) 2003-12-31
NO20020751D0 (no) 2002-02-15
AU6913200A (en) 2001-03-13
WO2001012205A2 (en) 2001-02-22
PL353769A1 (en) 2003-12-01
KR20020038728A (ko) 2002-05-23
IL148189A0 (en) 2002-09-12
NO20020751L (no) 2002-04-17
MXPA02001724A (es) 2004-09-06
CA2382293A1 (en) 2001-02-22
CN1378456A (zh) 2002-11-06

Similar Documents

Publication Publication Date Title
US20110076344A1 (en) Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
Brunda et al. In vivo anti‐tumor activity of combinations of interferon alpha and interleukin‐2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells
Bhardwaj et al. Interferon-gamma-activated human monocytes inhibit the intracellular multiplication of Legionella pneumophila.
Morstyn et al. Hemopoietic growth factors: a review
Caspar et al. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor [see comments]
Owen-Schaub et al. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor α and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity
Gajewski et al. Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations.
Zhang et al. Mobilization of dendritic cell precursors into the circulation by administration of MIP-1α in mice
Kaplan et al. The effect of recombinant human granulocyte macrophage colony-stimulating factor on neutrophil activation in patients with refractory carcinoma
Zhang et al. Pseudomonas aeruginosa Mannose-Sensitive Hemagglutinin Promotes T-Cell Response via Toll-Like Receptor 4–Mediated Dendritic Cells to Slow Tumor Progression in Mice
Wang et al. Interleukin‐10 induces macrophage apoptosis and expression of CD16 (FcγRIII) whose engagement blocks the cell death programme and facilitates differentiation
Myers et al. Interleukin‐12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long‐term antitumor immunity in syngeneic C3H mice
Aiura et al. Interaction with Autologous Platelets Multiplies Interleukin-l and Tumor Necrosis Factor Production in Mononuclear Cells
EP0768889B1 (en) Cancer therapy using lymphotoxin
NZ517673A (en) Chemically-stabilized chlorite solutions for treating cancer and other diseases
Tadokoro et al. Bone marrow-derived macrophages grown in GM-CSF or M-CSF differ in their ability to produce IL-12 and to induce IFN-γ production after stimulation with Trypanosoma cruzi antigens
Del Rosario et al. Prevention of graft-versus-host disease by induction of immune tolerance with ultraviolet B-irradiated leukocytes in H-2 disparate bone marrow donor
Richards et al. Phase I study of weekly 24-hour infusions of recombinant human interleukin-2
Krahenbuhl et al. Effects of Corynebacterium parvum treatment and Toxoplasma gondii infection on macrophage-mediated cytostasis of tumour target cells.
CA2324199A1 (en) Chronic lymphocytic leukemia treatment
Malone et al. Combination interferon-α2a and 13-cis-retinoic acid enhances radiosensitization of human malignant glioma cells in vitro
Hofmann et al. Activity of phagocytic granulocytes in patients with prostatic cancer
Oberbeck et al. Metoclopramide and cellular immune functions during polymicrobial sepsis
Rao et al. Administration of silica sensitizes lipopolysaccharide responsiveness of murine macrophages but inhibits T and B cell priming by inhibition of antigen presenting function
Factor Synergy of Tumor Necrosis Factor and Interleukin 2 in the

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed